EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Prevalence of antibody drug conjugated–induced nausea and vomiting (ADCINV) in patients with cancer

Ronald Chow, Daniel Zhang, Samy Kannout, Andreas Ma, Cindy Zheng, Ayden Blayne, Aaron Dou, Sumeet Talwar, Rouhi Fazelzad, Hope S Rugo, Christina H Ruhlmann, Hirotoshi Iihara und 5 weitere

Supportive Care in Cancer · 2026-05 · 34 (5)

DOI: 10.1007/s00520-026-10674-2 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Supportive Care in Cancer, online erschienen am 02.05.2026. Verfasst von Ronald Chow und 16 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. ronald.chow@uhn.ca. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunoconjugates, Nausea, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Antibody–drug conjugates (ADC) have emerged as an important part of systemic treatment across disease sites. To date, there is no robust pooled prevalence estimate of nausea and vomiting induced by ADCs. Establishing such estimates is essential to determine if ADC-induced nausea and vomiting (ADCINV) represents a clinically significant problem warranting further research into antiemetic prophylaxis. Our aim is to report the prevalence of reported ADCINV across literature.

Methods

A systematic search of Medline, Embase, Cochrane CENTRAL and Web of Science was conducted from database inception until September 24, 2025. Articles were included if they reported nausea and/or vomiting due to ADCs used in cancer treatment, in the abstract. Pooled prevalence was reported. Subgroup analysis was conducted by ADC. Meta-regression was conducted by age and sex. Quality assessment was conducted. Type I error was set at 0.05.

Results

A total of 209 studies with 15,493 patients were included. Thirty-nine percent (95%CI, 36–42%) of patients experience any nausea, and 26% (95%CI, 23–29%) experience any vomiting. Younger patients are more likely to experience nausea; each 10-year increase in age is associated with a 12% decrease in nausea rates. Higher emetogenic ADCs include trastuzumab deruxtecan, sacituzumab govitecan, brentuximabvedotin and patritumab deruxtecan. Lower emetogenic agents include disitimab vedotin, telisotuzumab vedotin and rovalpituzumab tesirine.

Discussion

This is the first study to report prevalence of ADCINV across ADCs. It is a prevalent adverse effect akin to chemotherapy-induced nausea and vomiting that should be viewed as clinically relevant and further investigated to help develop optimal strategies related to antiemetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsImmunoconjugatesNauseaNeoplasmsVomitingHumansAntiemeticsPrevalence

Stichwörter der Autor:innen

Antibody drug conjugateNauseaVomiting

Substanzen

AntiemeticsAntineoplastic AgentsImmunoconjugates

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. ronald.chow@uhn.ca.
  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. ronald.chow@uhn.ca.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. ronald.chow@uhn.ca.
  • Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK. ronald.chow@uhn.ca.
  • Siebel School of Computing and Data Science, University of Illinois Urbana-Champaign, Champaign, IL, USA.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Zitieren

APA

Chow, R., Zhang, D., Kannout, S., Ma, A., Zheng, C., Blayne, A., Dou, A., Talwar, S., Fazelzad, R., Rugo, H. S., Ruhlmann, C. H., Iihara, H., Affronti, M. L., Leigh, J., Scotté, F., Eng, L., & MASCC Antiemetic Study Group and the MASCC Emerging Toxicities Study Group (2026). Prevalence of antibody drug conjugated–induced nausea and vomiting (ADCINV) in patients with cancer. Supportive Care in Cancer, 34(5). https://doi.org/10.1007/s00520-026-10674-2

Vancouver

Chow R, Zhang D, Kannout S, Ma A, Zheng C, Blayne A, et al. Prevalence of antibody drug conjugated–induced nausea and vomiting (ADCINV) in patients with cancer. Supportive Care in Cancer. 2026;34(5). doi:10.1007/s00520-026-10674-2

BibTeX
@article{Chow2026,
  author = {Chow, Ronald and Zhang, Daniel and Kannout, Samy and Ma, Andreas and Zheng, Cindy and Blayne, Ayden and Dou, Aaron and Talwar, Sumeet and Fazelzad, Rouhi and Rugo, Hope S and Ruhlmann, Christina H and Iihara, Hirotoshi and Affronti, Mary Louise and Leigh, Jennifer and Scotté, Florian and Eng, Lawson and MASCC Antiemetic Study Group and the MASCC Emerging Toxicities Study Group, MASCC Antiemetic Study Group and the MASCC Emerging Toxicities Study Group},
  title = {Prevalence of antibody drug conjugated–induced nausea and vomiting (ADCINV) in patients with cancer},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {5},
  doi = {10.1007/s00520-026-10674-2}
}
Kostenlos starten →